HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

How Does Ridinilazole Compare with Other Antibiotics That Target C. diff?

Strategic Alliance Partners | <b>C Diff Foundation</b>

Dr. Richard Vickers, explains how ridinilazole is unique in its spectrum of activity compared with other antibiotics that target C. diff and have been approved or are in development.

Dr. Richard Vickers, chief scientific officer of R&D at Summit Therapeutics, explains how ridinilazole is unique in its spectrum of activity compared with other antibiotics that target C. diff and have been approved or are in development.

Interview Transcript (modified slightly for readability):

“Ridinilazole is really quite unique in its spectrum of activity. We know antibiotics like fidaxomicin, which was approved around 2011, was branded as a narrow-spectrum agent, and it’s a very good drug, it does work in minimizing recurrences, but it still has activity against numerous important members of the gut microbiota. There are other organizations that have drugs earlier in development than Summit Therapeutics is with ridinilazole that have a narrow-spectrum of activity. But certainly, based on the data generated to date, this profile we see with ridinilazole is quite unique; it’s really quite remarkable and hits that desired profile that you want for a new Clostridium difficile (C. diff ) antibiotic.”